ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,249.50
0.00%
S&P ASX All Technology
3,816.80
0.00%
Brent Oil
73.545
-0.85%
US Dollar vs AUD
1.5699
-0.17%
Bitcoin
106,199.02
1.78%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. OS Therapies Incorporated (OSTX)

  7. OS Therapies Incorporated (OSTX) News

OSTX

OS Therapies (OSTX)

OS Therapies Incorporated
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:OSTX
DateTimeSourceHeadlineSymbolCompany
16/11/202408:05Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
16/11/202401:47Business WireOS Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateAMEX:OSTXOS Therapies Incorporated
16/11/202401:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OSTXOS Therapies Incorporated
15/11/202408:58Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBAMEX:OSTXOS Therapies Incorporated
04/11/202423:00Business WireOS Therapies to Present at The Spartan Capital Investor ConferenceAMEX:OSTXOS Therapies Incorporated
02/11/202408:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
30/10/202423:51Business WireJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on October 30AMEX:OSTXOS Therapies Incorporated
30/10/202407:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
29/10/202407:55Edgar (US Regulatory)Form 8-K - Current reportAMEX:OSTXOS Therapies Incorporated
29/10/202407:44Business WireOS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsAMEX:OSTXOS Therapies Incorporated
24/10/202423:46Business WireOS Therapies to Present at the LD Micro Main Event XVIIAMEX:OSTXOS Therapies Incorporated
18/10/202400:22Business WireOS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitAMEX:OSTXOS Therapies Incorporated
03/10/202422:00Business WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient VisitAMEX:OSTXOS Therapies Incorporated
13/09/202422:09Business WireOS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesAMEX:OSTXOS Therapies Incorporated
05/09/202422:22Business WireOS Therapies to Present at H.C. Wainright 26th Annual Global Investment ConferenceAMEX:OSTXOS Therapies Incorporated
29/08/202421:53Business WireOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment DoseAMEX:OSTXOS Therapies Incorporated
22/08/202422:00Business WireOS Therapies Appoints Borys Shor, PhD to ADC Advisory BoardAMEX:OSTXOS Therapies Incorporated
22/08/202420:00Business WireOS Therapies Clarifies CUSIP of Common StockAMEX:OSTXOS Therapies Incorporated
19/08/202422:30Business WireOS Therapies Accepted Into Johnson & Johnson Innovation - JLABSAMEX:OSTXOS Therapies Incorporated
02/08/202422:55Business WireOS Therapies Forms Osteosarcoma Patient Advocacy Advisory BoardAMEX:OSTXOS Therapies Incorporated
01/08/202423:19Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202423:16Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202423:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202423:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202423:08Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OSTXOS Therapies Incorporated
01/08/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:OSTXOS Therapies Incorporated
01/08/202408:21Business WireOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”AMEX:OSTXOS Therapies Incorporated
31/07/202404:41Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingAMEX:OSTXOS Therapies Incorporated
31/07/202404:29Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]AMEX:OSTXOS Therapies Incorporated
25/07/202400:48Business WireOS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast CancerAMEX:OSTXOS Therapies Incorporated
 Showing the most relevant articles for your search:AMEX:OSTX

Your Recent History

ASX
NCM
Newcrest Mining
ASX
WES
Wesfarmers
ASX
AMP
AMP
SPI
SP500
S&P 500
NASDAQ
AMZN
Amazon.com
COIN
ADAUSD
Cardano
ASX
MQG
Macquarie
CCOM
SILVER
SILVER
ASX
WDC
Westfield
FX
AUDJPY
AUD vs Yen
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AAPL
Apple
ASX
XAO
Australian SE All Ordina...
ASX
SUN
Suncorp
ASX
XFL
S&P ASX 50
ASX
QBE
QBE Insurance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved